Carrimycin may exert its function through PI3K/AKT/mTOR pathway and MAPK pathway in oral squamous cell carcinoma cells, while suppressing tumor growth of hepatocellular carcinoma by inhibition of VEGF and PD-L1 protein expression [3, 4]. Here, AKT1 is linked to neoplasm.